GLPG

AcronymDefinition
GLPGGreen Lanes Protection Group (UK)
GLPGGrain Loan Program by Government
GLPGGlenn Procedures and Guidelines (US NASA)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
Galapagos (Euronext and NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz.
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve.
The triple pill has confirmed Phase III pivotal data coming Q4 and upcoming competitor Galapagos NV (GLPG) data "probably will eventually disappoint," claims the analyst.
JPMorgan analyst Cory Kasimov views yesterday's "relatively underwhelming" updates from Galapagos NV (GLPG) for its Pelican trial of corrector GLPG2737 given in conjunction with Orkambi as a "meaningful positive development" for Vertex Pharmaceuticals (VRTX).
Vertex Pharmaceuticals (VRTX), up 9% after several analysts said they viewed the updates from Galapagos' (GLPG) Pelican trial of corrector GLPG2737 as a positive development for Vertex.
Biotechnology company Galapagos NV (Euronext: GLPG) and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain).
ALSO LOWER: Galapagos NV (GLPG) down 13.4% after phase 2 data of GLPG2737; Convergys (CVG) down 1.5% after Synnex confirmed acquisition.
Gilead Sciences (GILD) and Galapagos NV (GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20 percent improvement score.
Biotechnology company Galapagos NV (Euronext: GLPG) has reached milestones in its osteoporosis alliance with Eli Lilly and Company (NYSE:LLY), resulting in payments of EUR2.9m from Lilly, the company announced today.
Gilead (GILD) and Galapagos NV (GLPG) announced that the randomized, placebo-controlled Phase 2 EQUATOR study of filgotinib, an investigational, selective JAK1 inhibitor, in 131 adults with moderate to severe psoriatic arthritis, achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16, as assessed by the American College of Rheumatology 20% improvement score.